IGM Biosciences IGMS Stock
IGM Biosciences Price Chart
IGM Biosciences IGMS Financial and Trading Overview
IGM Biosciences stock price | 1.13 USD |
Previous Close | 9.98 USD |
Open | 9.95 USD |
Bid | 0 USD x 900 |
Ask | 0 USD x 1100 |
Day's Range | 9.9 - 10.33 USD |
52 Week Range | 9.74 - 28.2 USD |
Volume | 206.66K USD |
Avg. Volume | 278.52K USD |
Market Cap | 434.55M USD |
Beta (5Y Monthly) | -0.241701 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.24 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 31.6 USD |
IGMS Valuation Measures
Enterprise Value | 102.45M USD |
Trailing P/E | N/A |
Forward P/E | -1.9571986 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 273.13123 |
Price/Book (mrq) | 1.8145744 |
Enterprise Value/Revenue | 64.393 |
Enterprise Value/EBITDA | -0.44 |
Trading Information
IGM Biosciences Stock Price History
Beta (5Y Monthly) | -0.241701 |
52-Week Change | -33.98% |
S&P500 52-Week Change | 20.43% |
52 Week High | 28.2 USD |
52 Week Low | 9.74 USD |
50-Day Moving Average | 11.5 USD |
200-Day Moving Average | 18.06 USD |
IGMS Share Statistics
Avg. Volume (3 month) | 278.52K USD |
Avg. Daily Volume (10-Days) | 348.22K USD |
Shares Outstanding | 29.51M |
Float | 9.28M |
Short Ratio | 20.73 |
% Held by Insiders | 38.12% |
% Held by Institutions | 61.95% |
Shares Short | 4.37M |
Short % of Float | 37.00% |
Short % of Shares Outstanding | 10.10% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -15045.50% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -41.52% |
Return on Equity (ttm) | -102.94% |
Income Statement
Revenue (ttm) | 1.59M USD |
Revenue Per Share (ttm) | 0.04 USD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 1.07M USD |
EBITDA | -232859008 USD |
Net Income Avi to Common (ttm) | -228516992 USD |
Diluted EPS (ttm) | -4.73 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 373.4M USD |
Total Cash Per Share (mrq) | 8.64 USD |
Total Debt (mrq) | 41.29M USD |
Total Debt/Equity (mrq) | 17.25 USD |
Current Ratio (mrq) | 8.818 |
Book Value Per Share (mrq) | 5.544 |
Cash Flow Statement
Operating Cash Flow (ttm) | -17961000 USD |
Levered Free Cash Flow (ttm) | -97122752 USD |
Profile of IGM Biosciences
Country | United States |
State | CA |
City | Mountain View |
Address | 325 East Middlefield Road |
ZIP | 94043 |
Phone | (650) 965-7873 |
Website | https://igmbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 280 |
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Q&A For IGM Biosciences Stock
What is a current IGMS stock price?
IGM Biosciences IGMS stock price today per share is 1.13 USD.
How to purchase IGM Biosciences stock?
You can buy IGMS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for IGM Biosciences?
The stock symbol or ticker of IGM Biosciences is IGMS.
Which industry does the IGM Biosciences company belong to?
The IGM Biosciences industry is Biotechnology.
How many shares does IGM Biosciences have in circulation?
The max supply of IGM Biosciences shares is 59.78M.
What is IGM Biosciences Price to Earnings Ratio (PE Ratio)?
IGM Biosciences PE Ratio is now.
What was IGM Biosciences earnings per share over the trailing 12 months (TTM)?
IGM Biosciences EPS is -3.24 USD over the trailing 12 months.
Which sector does the IGM Biosciences company belong to?
The IGM Biosciences sector is Healthcare.
IGM Biosciences IGMS included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3904.12 USD — |
-5.49
|
— — | 3901.51 USD — | 4064.61 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}